Business Context and Reporting Period
This Form 8-K, dated January 10, 2020, reports that OncoCyte Corporation (OCX) entered into a definitive Merger Agreement to acquire Insight Genetics, Inc. ("Insight") through a wholly-owned subsidiary. The filing details the terms of the proposed acquisition, which has been approved by the boards of both companies but has not yet closed.
Key Financial Metrics and Transaction Terms
The filing does not provide OncoCyte's current revenue, profit, cash flow, or debt metrics. Financial data is limited to the proposed transaction structure:
- Closing Consideration: $7 million in cash and $5 million in OncoCyte common shares (approximately 1.9 million shares).
- Holdback: Up to 10% of the total consideration ($700,000 cash and $500,000 in shares) held for indemnity claims, releasable within 60 days after December 31, 2020.
- Earnout Consideration: A ten-year revenue share of up to 10% of net collected revenues for current Insight pharma services, plus tiered revenue shares for new cancer tests developed using Insight technology.
- Milestone Payments: Up to $6.0 million contingent on specific achievements:
- $1.5 million for clinical trial completion and data publication.
- $3.0 million for an affirmative final local coverage determination from CMS for a specified lung cancer test.
- Up to $1.5 million for achieving specified CMS reimbursement milestones.
Material Changes and Related Party Transactions
The primary material change is the entry into the Merger Agreement. A significant related party transaction involves Ron A. Andrews, OncoCyte's President, CEO, and board member:
- Mr. Andrews holds a membership interest in IG Investors, LLC, which holds a convertible promissory note and warrants from Insight.
- Upon closing, Mr. Andrews is estimated to receive $0.7 million in cash, having agreed to forfeit $0.4 million in additional consideration.
- He has agreed to re-assign his membership interest, cancel his warrant rights, and will not receive any OncoCyte common shares or earnout consideration.
Outlook, Risks, and Contingencies
The filing contains extensive forward-looking statements regarding the merger's success. Key risks and contingencies include:
- Closing Conditions: The merger is subject to regulatory approval, accuracy of representations, and the absence of dissenters' rights. Insight must place trade secrets in escrow.
- Termination: Either party may terminate the agreement if the closing does not occur by March 31, 2020.
- Integration Risks: Potential difficulties in conforming business practices, retaining personnel, and realizing anticipated synergies.
- Regulatory and Commercial Risks: Uncertainty in clinical trial results, changes in regulatory requirements, and the need to obtain third-party reimbursement for diagnostic tests.
Investor Verification Checklist
- Verify the closing date and whether the March 31, 2020 termination deadline is met.
- Confirm the final share price used to calculate the 1.9 million shares issued to Insight shareholders.
- Monitor the status of the CMS local coverage determination for the lung cancer test, which triggers a $3.0 million milestone.
- Review the escrow agreement regarding Insight's trade secrets and intellectual property.
- Assess OncoCyte's liquidity to fund the $7 million cash portion of the deal and potential milestone payments.